Department of Critical Care Medicine, Xiangya Hospital, Central South University, Changsha, China.
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Front Immunol. 2023 Jan 27;14:1102126. doi: 10.3389/fimmu.2023.1102126. eCollection 2023.
In sepsis, brain dysfunction is known as Sepsis-associated encephalopathy (SAE), which often results in severe cognitive and neurological sequelae and increases the risk of death. Our systematic review and meta-analysis aimed to explore the diagnostic and prognostic value of serum S100 calcium-binding protein B (S100B) in SAE patients.
We conducted a systematic search of the databases PubMed, Web of Science, Embase, Cochrane databases, CNKI, VIP, and WFSD from their inception dates until August 20, 2022. A Meta-analysis of the included studies was also performed using Review Manager version 5.4 and Stata16.0.
This meta-analysis included 28 studies with 1401 serum samples from SAE patients and 1591 serum samples from no-encephalopathy septic (NE) patients. The Meta-Analysis showed that individuals with SAE had higher serum S100B level than NE controls (MD, 0.49 [95% CI (0.37)-(0.60), Z =8.29, < 0.00001]), and the baseline level of serum S100B in septic patients with burn was significantly higher than average (1.96 [95% CI (0.92)-(2.99), Z =3.71, P < 0.0002]) In addition, septic patients with favorable outcomes had lower serum S100B levels than those with unfavorable outcomes (MD, -0.35 [95% CI (-0.50)-(-0.20), Z =4.60, < 0.00001]).
Our Meta-Analysis indicates that higher serum S100B level in septic patients are moderately associated with SAE and unfavorable outcomes (The outcomes here mainly refer to the mortality). The serum S100B level may be a useful diagnostic and prognostic biomarker of SAE.
在脓毒症中，脑功能障碍被称为脓毒症相关性脑病（SAE），它常导致严重的认知和神经后遗症，并增加死亡风险。我们的系统评价和荟萃分析旨在探讨血清 S100 钙结合蛋白 B（S100B）在 SAE 患者中的诊断和预后价值。
我们对 PubMed、Web of Science、Embase、Cochrane 数据库、CNKI、VIP 和 WFSD 数据库进行了系统检索，检索时间从建库至 2022 年 8 月 20 日。使用 Review Manager 版本 5.4 和 Stata16.0 对纳入的研究进行荟萃分析。
这项荟萃分析纳入了 28 项研究，共纳入了 1401 例 SAE 患者的血清样本和 1591 例非脑病脓毒症（NE）患者的血清样本。荟萃分析显示，SAE 患者的血清 S100B 水平高于 NE 对照组（MD，0.49 [95%CI（0.37）-（0.60）]，Z=8.29，<0.00001），烧伤脓毒症患者的血清 S100B 基线水平明显高于平均水平（1.96 [95%CI（0.92）-（2.99）]，Z=3.71，P<0.0002）。此外，预后良好的脓毒症患者的血清 S100B 水平低于预后不良的患者（MD，-0.35 [95%CI（-0.50）-（-0.20）]，Z=4.60，<0.00001）。
我们的荟萃分析表明，脓毒症患者的血清 S100B 水平升高与 SAE 和不良结局中度相关（这里的结局主要是指死亡率）。血清 S100B 水平可能是 SAE 的一种有用的诊断和预后生物标志物。
Zotero 插件
